Funding opportunities for FY19–DOD Breast Cancer Research Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY19 Defense Appropriation provides $130 million to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.

FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)

  • Identify determinants of breast cancer initiation, risk, or susceptibility

  • Distinguish deadly from non-deadly breast cancers

  • Conquer the problems of overdiagnosis and overtreatment

  • Identify what drives breast cancer growth; determine how to stop it

  • Identify why some breast cancers become metastatic

  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

  • Eliminate the mortality associated with metastatic breast cancer

https://cdmrp.army.mil/funding/bcrp

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login